Up to a quarter of type 1 diabetes patients in England should have access to the Freestyle Libre, a flash glucose monitor that allows diabetics to check their blood sugar without the need for finger pricks. But a recent investigation by the BMJ has concluded that, in reality, just 3 to 5 percent of eligible patients have access to the potentially life-changing technology.

It’s not just what people eat—but when—that may influence their risk of developing prediabetes and high blood pressure, according to preliminary research scheduled to be presented Nov. 10 at the American Heart Association’s Scientific Sessions in Chicago.

Climbing rates of violent crime could trigger blood pressure (BP) spikes within nearby communities—particularly among individuals living in what are considered “safe” neighborhoods—according to a study of 50,000 adults living in Chicago.

Roux-en-Y gastric bypass (RYGB) is linked to greater weight loss compared to two other bariatric procedures but also the highest risk of adverse events in the short term, researchers reported in the Annals of Internal Medicine.

Cannabis use is associated with double the risk of diabetic ketoacidosis among patients with type 1 diabetes, according to a research letter published Nov. 5 in JAMA Internal Medicine.

A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.

Low-risk patients with mild hypertension derived no protective benefit from blood pressure drugs over 5.8 years of follow-up but had an increased risk of adverse effects potentially related to the medication, researchers reported in a new study.

With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.